|Bid||7.15 x 1000|
|Ask||7.20 x 900|
|Day's Range||7.10 - 7.49|
|52 Week Range||1.50 - 10.65|
|PE Ratio (TTM)||54.62|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.42|
SAN DIEGO, July 03, 2018-- Sorrento Therapeutics, Inc. announced today that it acquired the Sofusa™ lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, ...
LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.
The notes will be convertible into shares of Sorrento common stock at a price of $7.0125 per share and will accrue interest at a rate of 5% per year. Each purchaser of the convertible notes will also receive a warrant to purchase 50% of the number of shares of Sorrento common stock into which such purchaser’s note is initially convertible. Following the closing, we expect to have approximately $50m cash on hand to execute our business plan for the remainder of 2018.
Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules. Striving to catch up with New York and Shanghai as an IPO hotspot, the Hong Kong Stock Exchange announced new policies late last year that actively court biotech companies, including those that do not have a drug on the market.
When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent. Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules.
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).
I am going to run you through how I calculated the intrinsic value of Sorrento Therapeutics Inc (NASDAQ:SRNE) using the discounted cash flow (DCF) method. If you want to learnRead More...
NEW YORK, May 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sunstone ...
Investor attention will now shift to President Trump's decision on the Iran nuclear accord on Tuesday at 2:00 p.m. The Dow Jones Industrial Average gained 0.39 percent to close at 24,357.32, while the S&P 500 Index rose 0.35 percent to close at 2,672.63. The Nasdaq Composite Index jumped 0.77 percent to close at 7,265.21. If Trump pulls out, which other leaders have urged him not to do, then supply will be cut, which will have the same impact as rising demand in terms of driving up prices.
NEW YORK , April 24, 2018 /PRNewswire/ -- Cancer Genetics, Inc. (CGIX) Lifshitz & Miller announces investigation into possible securities law violations in connection with Cancer Genetics' announcement ...
Dr. Ji will share his vision for the future of cellular immunotherapy using Sorrento’s anti-CD38 and anti-BCMA CAR-T cell therapy programs for treatment of Multiple Myeloma as examples. Dr. Ji will also discuss the utilization of allogeneic cell sources, including placental immune cells as well as gamma/delta T cells, for improving patient access and potentially reducing cost of cell therapies.
Sorrento Therapeutics (SRNE) is a clinical-stage biotechnology company. Its research programs are targeted at autoimmune, inflammatory, and neurodegenerative diseases and pain indications. Essentially, Sorrento Therapeutics is an antibody-centric company and leverages its G-MAB library to generate product candidates.
Sorrento Therapeutics (SRNE) aims to use its antibodies along with its proprietary targeted delivery modalities to generate therapies for cancer. Additionally, Sorrento Therapeutics has acquired late-stage biosimilar antibodies based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics expects to submit an Investigational New Drug Application (or IND) for at least one of these two programs with the FDA in 2018.